---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-022354"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:37:59.800288+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# European patent granted covering brilaroxazine for pulmonary hypertension; adds to US, China, Japan patents

## Summary
- European Patent EP3244896 granted covering brilaroxazine for treating PH, PAH, including PH in COPD or SCD patients.
- Similar patents already granted in United States, China, and Japan for brilaroxazine in PH/PAH.
- Brilaroxazine has Orphan Drug Designation from FDA for treatment of pulmonary arterial hypertension.
- CEO cites anti-inflammatory/antifibrotic activity in animal models; plans to evaluate PH/PAH expansion.

## SEC filing metadata
- accession: 0001437749-24-022354
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774924022354/0001437749-24-022354-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774924022354/rvph20240709_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-022354
- JSON: https://secwatch.observer/filing/0001437749-24-022354.json
- Plain text: https://secwatch.observer/filing/0001437749-24-022354.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.